Estrogens reduce adipose tissue mass in both humans and animals. The molecular mechanisms for this effect are, however, not well characterized. We took a gene expression profiling approach to study the direct effects of estrogen on mouse white adipose tissue (WAT). Female ovariectomized mice were treated for 10, 24 and 48 h with 17 -estradiol or vehicle. RNA was extracted from gonadal fat and hybridized to Affymetrix MG-U74Av2 arrays. 17 -Estradiol was shown to decrease mRNA expression of liver X receptor (LXR) after 10 h of treatment compared with the vehicle control. The expression of several LXR target genes, such as sterol regulatory element-binding protein 1c, apolipoprotein E, phospholipid transfer protein, ATP-binding cassette A1 and ATP-binding cassette G1, was similarly decreased. We furthermore identified a 1·5 kb LXR promoter fragment that is negatively regulated by estrogen. Several genes involved in lipogenesis and lipolysis were identified as novel targets that could mediate estrogenic effects on adipose tissue. Finally, we show that ER is the main estrogen receptor expressed in mouse white adipose tissue (WAT) with mRNA levels several hundred times higher than those of ER mRNA.
Introduction
The prevalence of obesity is rapidly increasing in the western world (Kuczmarski et al. 1994) . Obesity is associated with an increased risk of several diseases, such as type 2 diabetes, cardiovascular disease and cancer in breast, prostate, endometrium, colon and gallbladder (Bray 2002) . Obesity is the result of increases in adipocyte number and size (Faust et al. 1978) . Adipocyte size is determined by the balance between lipid synthesis (lipogenesis) and lipid breakdown (lipolysis) (Prins & O'Rahilly 1997) . Lipogenesis, which involves fatty acid synthesis and subsequent triglyceride (TG) synthesis, occurs in both adipose tissue and liver (Eckel 1989) . Lipolysis is the hydrolysis of TG, stored in adipocytes, to free fatty acids and glycerol (Langin et al. 1996) . When a critical adipocyte size is reached, further fat accumulation causes an increase in adipocyte number (Faust et al. 1978) .
Women generally have more body fat than men and a higher proportion of fat in the glutealfemoral region, the so-called gynoid fat distribution (Blaak 2001) . Men generally have more body fat in the abdominal (visceral or central) region, which is called an android fat distribution (Blaak 2001) . After menopause, women accumulate more intraabdominal fat and therefore obtain an increased central adiposity (Poehlman 2002) . In particular, this central distribution of body fat is a powerful and independent predictor of disease (Poehlman 2002) .
Estrogens have important effects on many tissues in the body, among them adipose tissue (Mueller & Korach 2001) . Estrogen could influence adipose tissue mass by both central and peripheral effects. Regulation via the central nervous system includes behavioral regulation of feeding and physical activity. Peripheral effects are exerted directly on the adipose tissue. A correlation between estrogen and adipose tissue mass has been seen in both humans and rodents (Heine et al. 2000) . An increased adipose mass is seen in women after menopause when estrogen levels decrease, while estrogen replacement therapy decreases adipose mass (Tchernof et al. 1998) . Ovariectomy and estrogen treatment in rodents have similar effects on adipose tissue to those seen in humans (Wade & Gray 1979) . Estrogen reduces food intake, which is postulated to occur partly via increased cholecystokinin-signaling and negative feedback on meal size (Geary 2001) . There are also reports on increased running-wheel activity in estrogentreated mice, primarily mediated through estrogen receptor (ER) (Ogawa et al. 2003) . Estrogens are also known to decrease adipose tissue mass by increasing lipolysis (Lincova et al. 1984 , Tomita et al. 1984 , but the molecular mechanisms for this phenomenon are still unclear. Furthermore, postmenopausal women have reduced energy expenditure (Poehlman 2002) .
Estrogen exerts its effects via two nuclear receptors, ER and ER (Nilsson et al. 2001) . The receptors function as ligand-dependent transcription factors that bind to estrogen response elements (EREs) or, for example, in association with fos and jun, to activator protein 1 (AP-1) sites in target gene promoters (Nilsson et al. 2001) . ER mRNA and protein expression (Price & O'Brien 1993 , Mizutani et al. 1994 and ER mRNA expression (Crandall et al. 1998 , Pedersen et al. 2001 have been detected in human adipose tissue. In mouse and rat adipose tissue, estrogen receptors have been detected by estradiol-binding (Seiki et al. 1978 , Wade & Gray 1978 , Haslam & Shyamala 1981 . However, to our knowledge, the relative levels of ER and have not been reported.
Knockout mouse models have shed light on the role of estrogen and its receptors in rodent obesity. Mice that lack aromatase (ArKO mice) are unable to synthesize endogenous estrogen and display an obese phenotype (Jones et al. 2000) . A similar phenotype is observed in mice lacking ER , but not in mice lacking ER , showing that ER is the major mediator of the down-sizing effects of estrogen on mouse fat mass (Heine et al. 2000 , Ohlsson et al. 2000 . In addition, ER has been shown to have anorectic effects mediated via the central nervous system (Liang et al. 2002b) . However, in another report, ER was indicated to have opposite effects to ER , as shown by decreased fat mass in ER knockout (ERKO) mice following ovariectomy (Naaz et al. 2002) .
Earlier reports have shown some mechanisms by which estrogen affects metabolism. Estrogen increases hormone-sensitive lipase, which is the rate-limiting enzyme in lipolysis (Palin et al. 2003) . Estrogen decreases lipoprotein lipase (LPL) enzyme activity in humans and animals, which is expected to lead ultimately to a decrease in TG deposition in fat cells (Homma et al. 2000 , Yamaguchi et al. 2002 . Estrogen also represses the activity of hepatic lipase, an enzyme that hydrolyzes TG and phospholipids in lipoproteins, resulting in an increase in high-density lipoprotein (HDL) cholesterol (Jones et al. 2002) .
To understand the effects of estrogen in relation to metabolic disease, we have begun to characterize its effects on adipose tissue at the molecular level. In this study, we use gene expression profiling to determine estrogen-regulated genes in mouse white adipose tissue (WAT).
Materials and methods

Animals
For determination of ER and ER expression levels, 11-week-old female C57BL/6 wild-type mice were ovariectomized or sham-operated. The animals were kept on soy-free diet for 1 week before they were killed at 13 weeks of age. Gonadal WAT and interscapular brown adipose tissue (BAT) were collected and stored at -80 C.
For microarray experiments, 8-week-old female C57BL/6 mice were ovariectomized. After recovery for 2 weeks, the mice were injected (subcutaneously) with 2·3 µg/mouse of 17 -estradiol (E2) and killed 10, 24 or 48 h after the injection. Control mice received injections of vehicle oil (olive oil, Apoteksbolaget, Göteborg, Sweden). Gonadal WAT and liver were collected and kept at -80 C. Arterial blood was sampled and centrifuged to obtain serum, in which E2 levels were measured using a radioimmunoassay monitoring E2 (DiaSorin, Saluggia, Italy) with a sensitivity of 10 pg/ml. All studies were approved by Stockholm South Ethical Committee for animal experiments and the ethical committee for animal care at Göteborg University.
Microarray analysis
RNA preparation and experimental design
Total RNA was prepared from gonadal WAT (n=7 for all groups), using Trizol Reagent as previously described (Chomczynski & Sacchi 1987) . RNA was further purified with the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). RNA samples were pooled into two pools (n=3 or 4 per pool) per treatment group. There were vehicle-treated and estradioltreated groups for each time point, generating 12 pools in total. RNA was reverse transcribed into cDNA, in vitro transcribed into cRNA and prepared for DNA microarray analysis according to the Affymetrix Gene Chip Expression Analysis manual (MG-U74Av2 array; Affymetrix, Santa Clara, CA, USA).
Bioinformatics
The scanned output files were analyzed with Affymetrix Microarray Suite Version 5·0 software. Comparisons were made between two estrogentreated and two vehicle-treated samples, generating four comparisons for each time point, using Affymetrix Data Mining Tool Version 3·0. Filters used for the presented data were as follows. For supplemental data, genes were included if the Affymetrix change algorithm gave increased (I) or decreased (D) calls respectively for all comparisons. Genes absent (A) according to the Affymetrix detection algorithm on both arrays of a comparison have been excluded. Furthermore, the average fold change was _2. For Table 1 , average fold changes are given for genes increased (I) or decreased (D) respectively in at least three out of four comparisons.
Real-time PCR analysis
Total RNA was prepared as described above. An amount of 1 µg of RNA from individual animals was reverse transcribed into cDNA using Reverse Transcription Reagents with random hexamer primers (Applied Biosystems, Foster City, CA, USA). Analysis was performed with the ABI Prism 7700 Sequence Detection System (Applied Biosystems). Primer sequences for apolipoprotein E (apoE), glucose-6-phosphate dehydrogenase (G6DH) and glycerol-3-phosphate acyltransferase (GPAT) (Liang et al. 2002a ) and sterol regulatory element-binding protein (SREBP) 1c (Stulnig et al. 2002) have been described previously. Additional primer and probe sequences are shown in Table 2 . A SYBR Greenbased protocol was used for apoE, G6PD and GPAT mRNA expression analysis. In this case, PCR products were further analyzed by melting curve analysis to confirm a single product. A TaqMan probe-based protocol was used for all other genes. mRNA levels were calculated by the 'Standard Curve Method' (multiplex reactions, according to instructions in User Bulletin no. 2, Applied Biosystems). mRNA expression levels were normalized to 18S rRNA in all studies except for the ER and ER expression study, where glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used (Applied Biosystems). In addition, known amounts of mouse ER and ER (Pettersson et al. 1997 ) and rat GAPDH (gift from Dr Christine Sadek, Department of Biosciences) plasmids were used as standards to calculate absolute amounts of the receptor mRNAs.
Plasmid constructs
The mouse liver X receptor (LXR) -1513/+1 promoter fragment was obtained by PCRamplification from a longer promoter fragment, using Taq Polymerase (Roche Diagnostics, Indianapolis, IN, USA) with primers 5 -TTAAT GACGCGTCATGGGAATTGGAGTTCACA-3 and 5 -GTCAGCCTCGAGTCCCCCCTCCTC CCAAA-3 incorporating MluI and XhoI restriction sites (underlined) respectively. The PCR product was cleaved with the appropriate enzymes and cloned into the pGL3-Basic Vector (Promega, Madison, WI, USA). The sequence of the promoter fragment was verified by DNA sequencing. An expression vector containing mouse ER cloned into the pSG5 vector (Stratagene, La Jolla, CA, USA) was used in the cotransfections (Pettersson et al. 1997) . Empty pGL3-Basic and pSG5 vectors were used as controls.
Transient transfections
Mouse hepatoma cells (Hepa) were cultured in DMEM containing 4·5 g/l glucose (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS, 100 U penicillin/ml and 100 µg streptomycin/ml. A total of 10 000 cells/well were seeded in 24-well Table 1 Genes involved in metabolism. Average fold changes are given for genes increased or decreased respectively in at least three out of four comparisons. Genes are marked if not changed (NC) in at least three out of four comparisons. The fold change was calculated from the signal log ratio (2 signal log ratio =fold change) and the average fold change of all four comparisons was included in the table. Sorting into groups was done according to the references included in the table. The accession numbers were accessed from www.affymetrix.com, using the Netaffx Analysis Center (Liu et al. 2003) .
# Genes mentioned in the text. *Genes increased from absent to present or decreased from present to absent, which could give less accurate fold changes. plates 20 h before transfection in phenol red-free, high-glucose DMEM (Invitrogen) supplemented with 10% dextran-coated charcoal-treated FBS, 2 mM -glutamine, 1 mM sodium pyruvate, 100 U penicillin/ml and 100 µg streptomycin/ml. Mouse preadipocyte cells (3T3-L1K) were cultured in DMEM containing 4·5 g/l glucose (Invitrogen) supplemented with 10% calf serum, 2 mM -glutamine, 100 U penicillin/ml and 100 µg streptomycin/ml. A total of 20 000 cells/well were seeded in 24-well plates 16 h before transfection in the same charcoal-treated FBS-containing media as described above for Hepa. The -1513/+1 LXR promoter construct or empty pGL3-Basic vector (both expressing firefly luciferase as a reporter gene) was cotransfected with ER or empty pSG5 vector, using Lipofectamine 2000 in Opti-Mem I Reduced Serum Medium according to the standard protocol (Invitrogen). A plasmid-expressing Renilla luciferase under control of the thymidine kinase promoter (pRL-TK, Promega) was included as a positive control to exclude a general effect on transcription and/or translation of estrogen in the transfected cells. The medium was changed after 5 h to 
Results
ER and ER mRNA expression in mouse adipose tissue
mRNA levels of ER and ER are shown in Fig.  1A and B respectively. ER levels in WAT were approximately double those in BAT for both sham-operated and ovariectomized mice (Fig. 1A) . Low levels of ER mRNA could be detected in mouse adipose tissue by quantitative real-time PCR; however, ER is the main ER expressed in both WAT and BAT of mouse (Fig. 1C) .
Gene expression profiling identifies estrogen-regulated genes in mouse WAT
To identify estrogen-regulated signaling networks in mouse WAT, we treated mice with a single injection of E2. E2 levels were highest after 10 h and decreased with time ( Fig. 2A) . Gene expression profiles were analyzed after 10, 24 and 48 h treatment. An overview of the number of estrogen-regulated genes after the different treatment times is shown in Fig. 2B . The number of changed genes is highest after 24 h. The microarray results were confirmed with real-time PCR (Fig. 3) . Two genes with increased and two genes with decreased expression were selected for the confirmation. Genes involved in adipogenesis or lipogenesis and lipolysis were identified from the literature and are presented in Table 1 . Genes known to be increased in lipogenesis or adipogenesis, and that were decreased following estrogen treatment, are likely to play a role in the mechanism of estrogenic decrease of adipose tissue mass. CCAAT/enhancer-binding protein (C/EBP ), signal transducer and activator of transcription 1 (STAT1), retinol-binding protein (RBP) and pyruvate carboxylase were all decreased after 10 h treatment, as were lactate dehydrogenase-B and adiponectin after 24 h.
Genes known to be repressed in lipogenesis/ adipogenesis or increased during lipolysis might also play a role in decreasing adipose tissue mass. CHOP-10/GADD153 and uncoupling protein 1 (UCP1) were increased after 10 h, and alpha-1 type I procollagen after 24 h. Some receptors for lipolytic hormones were also increased, interleukin 1 receptor type II after 10 h and growth hormone receptor after 24 and 48 h, although the growth hormone receptor was decreased first (after 10 h).
Several other metabolism-associated genes were found to be under estrogenic control, such as low-density lipoprotein receptor (LDLR), fatty acid coenzyme A ligase long chain 2, insulin-like growth factor I receptor and insulin-like growth factor 2 receptor.
Many knockout mouse models exist with a phenotype of leanness and obesity resistance (Chen & Farese 2001) . Two of the genes knocked out in the leanness models, protein tyrosine phosphatase 1B and acyl-CoA:diacylglycerol acyltransferase (DGAT), decreased in expression after 10 h, and after 10 and 24 h of treatment respectively.
Several other regulated genes were found in this study. Many genes with increased expression following E2 administration are involved in cell adhesion, most of them encoding procollagens of different types. Several genes with increased expression represent heat-shock proteins involved in heat-shock response. Many genes with decreased expression are involved in transcription regulation, including some SRY-box containing genes.
LXR is a target gene for estrogen in WAT and liver
Interestingly, one gene found to be decreased 10 h after estrogen treatment was the nuclear receptor LXR . LXRs have been shown to play important roles in lipid and cholesterol metabolism . Recently, LXR double-knockout mice Figure 1 ER expression is much higher than ER expression in mouse WAT and BAT. ER mRNA expression in WAT and BAT in sham-operated and ovariectomized (OVX) 13-week-old female C57BL/6 mice (n=4) was analyzed with real-time PCR. (A) ER mRNA levels, (B) ER mRNA levels and (C) relative expression of ER and ER . Results presented are means±standard deviation normalized to GAPDH, with the first sample set to 1. In (C), known amounts of plasmids were used as standards in the calculation of the absolute amounts of receptor mRNAs. Statistical significance relies on Student's t-test: **P<0·01; ***P<0·001.
Figure 2
Serum estradiol levels and number of estrogen-regulated genes. (A) Serum estradiol levels were measured by a radioimmunoassay detecting estradiol with a sensitivity of 10 pg/ml (n=7). (B) Number of genes that were increased or decreased by E2 at each time point. Included genes were similarly regulated in all four comparisons (see Materials and methods) with average fold change >2.
were reported to have significantly decreased WAT and BAT (Juvet et al. 2003) . A 10-h estrogen treatment also repressed the mRNA levels of several known target genes normally upregulated by LXR , such as sterol regulatory elementbinding protein 1c , apolipoprotein E (apoE), phospholipid transfer protein (PLTP), ATP-binding cassette (ABC) A1 and ABCG1 (Table 3 ). The regulation of LXR and SREBP-1c observed with the Affymetrix gene chips was confirmed using real-time PCR analysis ( Fig. 4A and B). LXR was not regulated by estrogen in this Estrogen regulation of (A) apolipoprotein E (apoE), (B) glucose-6-phosphate dehydrogenase (G6PD), (C) glycerol-3-phosphate acyltransferase (GPAT) and (D) liver X receptor (LXR) was confirmed at different time points. RNA from individual mice (the same mice as for the gene expression profiling) was used (n=7). Results presented are means±standard deviation normalized to 18S, with the first sample set to 1. D=decreased, I=increased in three or four out of four comparisons (3/4 or 4/4, respectively); however, all comparisons were used for the calculation of average fold change. The numbers included are fold changes for the E2 vs vehicle treatments. Statistical significance relies on Student's t-test: *P<0·05; **P<0·01; ***P<0·001.
Table 3
Regulation of LXR target genes in fat as determined by Affymetrix analysis. Regulation is indicated with the average fold change as in Table 1 −1·2 10 h (4/4) Efflux of phospholipid and/or cholesterol (Venkateswaran et al. 2000) system (Fig. 4C) . Liver is another target organ for the metabolic effects of estrogen. Interestingly, estrogen decreases mRNA levels of LXR also in liver after 24 h of treatment (Fig. 5) .
The LXR promoter is repressed by estrogen
To determine whether the LXR promoter is a direct target for estrogen repression, an approximately 1·5 kb fragment of the 5 -flanking region of the mouse LXR gene (positions -1513 to +1), was cloned, as described in Materials and methods (Fig.  6A) . The construct was transiently transfected into Hepa cells and 3T3-L1K cells together with an ER expression plasmid as indicated. Estrogen treatment, in the presence of ER , decreases the activity of the firefly luciferase reporter gene by 60% in Hepa cells (Fig. 6B ) and 77% in 3T3-L1K cells (Fig. 6C) . A positive control was included to exclude a general effect on transcription and/or translation of estrogen in the transfected cells ( Fig. 6B-C) .
Discussion
In this paper, we describe the direct effects of estrogens on WAT gene expression. In particular, we demonstrate downregulation of LXR and several of its target genes after 10 h of estrogen treatment. Our findings are consistent with a recent report showing estrogen regulation of LXR in primary macrophages and leukemic, monocytic THP-1 cells (Kramer & Wray 2002) . However, our report is the first to demonstrate estrogen regulation of LXR in metabolic tissues. Furthermore, we demonstrate direct downregulation of the LXR promoter by estrogen. The studied fragment of the LXR promoter contains one estrogen response element (ERE) sequence with deviation from the consensus at three positions, and several AP-1 sites (Fig. 6A) . Further studies will be needed to determine whether these sites contribute to the observed downregulation of LXR by estrogen. Downregulation of LXR expression was observed only after 10 h of estrogen treatment. We speculate that levels of estrogen in WAT after 24 h are insufficient to maintain suppression of the LXR promoter. Estrogen action on adipose tissue could be mediated via LXR and its target genes. SREBP-1c activates genes involved in fatty acid synthesis . SREBP-1c-deficient mice have reduced plasma TGs and reduced mRNA levels of enzymes of fatty acid and TG synthesis (Liang et al. 2002a) . Therefore, the decrease in SREBP-1c following estrogen could explain the decrease in amount of adipose tissue seen after estrogen treatment.
Phospholipid transfer protein (PLTP), apoE, ABCA1 and ABCG1 are other target genes of LXR that were regulated by estrogen in this experiment. There has been one report of a decreased PLTP activity after 71 days of hormone replacement therapy in women (Ulloa et al. 2002) . Serum concentration of apoE was decreased by estrogen in prostate cancer patients (Usui et al. 2002) but was also found to be increased by estrogen in brain (Levin-Allerhand et al. 2001 ). Only two LXR target genes, fatty acid synthase (FAS) and lipoprotein lipase (LPL), were unchanged according to our criteria for assessing changed expression of genes. For LPL, however, the regulation by LXR was observed only in liver and macrophages, not in adipose tissue or muscle (Zhang et al. 2001) . Direct regulation of FAS by LXR has been shown before in HepG2 cells (Joseph et al. 2002) .
Several other important genes involved in lipid metabolism were found to be regulated by estrogen in adipose tissue. CCAAT enhancer-binding protein (C/EBP ) is required for differentiation of WAT and fat accumulation (Linhart et al. 2001) . C/EBP knockout mice die just after birth due to severe hypoglycemia, but they also fail to accumulate interscapular fat (Wang et al. 1995 , Flodby et al. 1996 . Since hepatic dysfunction was the major cause of lethality, mice expressing C/EBP exclusively in the liver were generated. These transgenic C/EBP knockout mice survived longer and lacked subcutaneous, perirenal and epididymal WAT already at 7 days of age (Linhart et al. 2001) .
Downregulation of C/EBP might play an important part in the mechanism of estrogeninduced decrease in adipose tissue, since, in this study, estrogen treatment decreased C/EBP expression. C/EBP is required for expression of the 3-adrenergic receptor during adipogenesis (Dixon et al. 2001) . The 3-adrenergic receptor was also downregulated after 10 and 24 h of estrogen treatment. Interestingly, peroxisome proliferator activated receptor (PPAR) was not regulated in our experiment. This lack of PPAR regulation was confirmed by real-time PCR (data not shown). Therefore, PPAR does not appear to be a direct target for estrogen in mouse fat.
One of the genes knocked out in mouse models of obesity resistance, acyl coenzyme A:diacylglycerol transferase, is responsible for the final step in the glycerol phosphate pathway of TG synthesis (Bray 2002) . These mice also show increased thermogenesis (Bray 2002) . The other knockout gene mentioned which leads to obesity resistance, protein tyrosine phosphatase-1B (PTP-1B), encodes an enzyme that terminates the action of phosphorylated tyrosines in receptors (Bray 2002) . The gene has been implicated in insulin resistance, since insulin resistance is reduced in this knockout (Bray 2002) .
Several of the regulated genes (Table 1 and data not shown) can serve as positive controls for the identification of estrogen-regulated genes, since they are known to be regulated by estrogen. They include the low-density lipoprotein receptor (LDLR) (Parini et al. 1997) , creatine kinase (Somjen et al. 1997 ) and the SRY-box containing gene 4 (Hunt & Clarke 1999) .
The identification of ER as the major ER in adipose tissue is in good agreement with previous findings of obesity in ER knockout mice, and supports the notion that direct ER -mediated effects of estrogens in adipose tissue decrease adipose mass.
Estrogen is known to affect fat mass in humans. It is possible that SERMs (selective estrogen receptor modulators) specifically targeting adipose tissue might provide therapeutic opportunities for obesity.
In conclusion, we have discovered that LXR represents an estrogen-regulated pathway in adipose tissue. Several metabolism-associated genes not previously known to be regulated by estrogens were identified as possible mediators of estrogeninduced reduction of adipose tissue, including SREBP-1c and C/EBPa. A large number of other estrogen-regulated genes were identified in mouse adipose tissue.
